ZNTL
Zentalis Pharmaceuticals, Inc.Company Information
- Company Name
- Zentalis Pharmaceuticals, Inc.
- CIK
- CIK0001725160
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ZNTL: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ZNTL
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-14
- Last sale
- 2026-02-10
- Shares purchased (TTM)
- 10,794,973
- Shares sold (TTM)
- 7,508,674
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 44,461,859
- Shares outstanding
- 71,326,000
- Ownership
- 62.34%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -24.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 25 | 32 | 36 | 39 | 38 | 42 | 34 | 41 | 37 | 38 | 28 | 111 | ||||||
| Available For Sale Securities Debt Securities | - | - | - | - | - | - | - | - | - | - | 455 | 406 | ||||||
| Investments | - | - | - | - | - | - | - | 350 | 389 | 451 | - | - | ||||||
| Available For Sale Securities Debt Securities Current | 150 | 180 | 210 | 239 | 249 | 278 | 318 | - | - | - | 455 | - | ||||||
| Equity Securities Fv Ni | - | - | 0 | 2 | 17 | 12 | 19 | - | - | - | 0 | - | ||||||
| Accounts Receivable Net Current | - | - | 0 | 0 | 0 | 0 | 5 | - | - | - | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 7 | 6 | 7 | 8 | 8 | 10 | 10 | 9 | 13 | 15 | 14 | 12 | ||||||
| Assets Current | 181 | 218 | 253 | 288 | 312 | 343 | 386 | 400 | 440 | 504 | 497 | 528 | ||||||
| Property Plant And Equipment Net | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 5 | 6 | 6 | 6 | ||||||
| Operating Lease Right Of Use Asset | 25 | 26 | 26 | 30 | 31 | 32 | 33 | 33 | 33 | 35 | 36 | 36 | ||||||
| Prepaid Expense And Other Assets Noncurrent | 4 | 4 | 4 | 3 | 3 | 3 | 4 | 6 | 7 | 7 | 7 | 9 | ||||||
| Equity Method Investments | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Goodwill | - | - | - | - | - | - | 0 | 4 | 4 | 4 | 4 | 4 | ||||||
| Restricted Cash Noncurrent | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Assets | 215 | 253 | 289 | 327 | 352 | 384 | 430 | 451 | 492 | 557 | 552 | 586 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 8 | 7 | 7 | 7 | 4 | 8 | 7 | 8 | 20 | 11 | 15 | 14 | ||||||
| Accrued Liabilities Current | 29 | 28 | 29 | 30 | 35 | 42 | 45 | 47 | 46 | 44 | 54 | 45 | ||||||
| Liabilities Current | 38 | 35 | 37 | 37 | 39 | 49 | 53 | 55 | 67 | 55 | 69 | 59 | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 40 | 41 | 43 | 43 | 43 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Liabilities | 72 | 70 | 73 | 74 | 77 | 89 | 93 | 96 | 109 | 99 | 114 | 104 | ||||||
Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,413 | 1,409 | 1,407 | 1,409 | 1,404 | 1,398 | 1,391 | 1,360 | 1,349 | 1,336 | 1,324 | 1,310 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 2 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,269 | -1,227 | -1,191 | -1,156 | -1,130 | -1,103 | -1,054 | -1,007 | -967 | -878 | -889 | -828 | ||||||
| Stockholders Equity | 144 | 183 | 216 | 253 | 274 | 295 | 337 | 354 | 383 | 459 | 437 | 482 | ||||||
| Liabilities And Stockholders Equity | 215 | 253 | 289 | 327 | 352 | 384 | 430 | 451 | 492 | 557 | 552 | 586 | ||||||
| Minority Interest | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 72 | 71 | 69 | 72 | 72 | 72 | 71 | 71 | 71 | 71 | 71 | 71 | ||||||
| Shares Outstanding | 72 | 71 | 69 | 72 | 72 | 72 | 71 | 71 | 71 | 71 | 71 | 71 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialZentalis Pharmaceuticals, Inc. (ZNTL) — SEC Financial Statements & Analysis
Zentalis Pharmaceuticals, Inc. (ZNTL) is a pharmaceutical preparations company. Zentalis Pharmaceuticals, Inc. trades on Nasdaq as: ZNTL. Zentalis Pharmaceuticals, Inc. (ZNTL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Zentalis Pharmaceuticals, Inc. carries a market cap of $345.93M, a P/E ratio of -2.48x, a P/B ratio of 2.41x, a P/S ratio of 4.05x, an enterprise value of $318.52M, and an EV/EBITDA multiple of -2.09x. On profitability, it posts an operating margin of -615.16%, a net margin of -555.80%, a Return on Equity (ROE) of -66.75%, a Return on Assets (ROA) of -49.22%, and a Return on Invested Capital (ROIC) of -87.38%. Per share, it reports EPS of $-1.96, diluted EPS of $-1.96, free cash flow per share of $-1.79, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -14.28% year-over-year, and EPS growth of -13.48% year-over-year. On the balance sheet, it maintains a current ratio of 4.82x, a quick ratio of 4.64x, working capital of $143.65M, a debt-to-equity ratio of 0.50x, a debt ratio of 0.33, free cash flow of $-127.81M (TTM), and net debt of $-27.41M. Figures sourced from SEC EDGAR.
- Market Cap
- $345.93M
- P/E TTM
- -2.48x
- EPS TTM
- $-1.96
- P/B TTM
- 2.41x
- ROE TTM
- -66.75%
- ROA TTM
- -49.22%
- Debt To Equity
- 0.50x
- Free Cash Flow TTM
- $-127.81M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Zentalis Pharmaceuticals, Inc. in?
Zentalis Pharmaceuticals, Inc. (ZNTL) operates in the Pharmaceutical Preparations industry.
What exchange does ZNTL trade on?
Zentalis Pharmaceuticals, Inc. (ZNTL) trades on the Nasdaq.
When was Zentalis Pharmaceuticals, Inc. (ZNTL)'s most recent SEC filing?
Zentalis Pharmaceuticals, Inc. (ZNTL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is ZNTL's market cap?
Zentalis Pharmaceuticals, Inc. (ZNTL) has a market capitalization of $345.93M as of 2026-06-30.
What is ZNTL's EPS (earnings per share)?
Zentalis Pharmaceuticals, Inc. (ZNTL)'s trailing twelve month EPS is $-1.96 as of 2026-06-30.
What is ZNTL's ROE (return on equity)?
Zentalis Pharmaceuticals, Inc. (ZNTL)'s trailing twelve month Return on Equity (ROE) is -66.75% as of 2026-06-30.
What is ZNTL's ROA (return on assets)?
Zentalis Pharmaceuticals, Inc. (ZNTL)'s trailing twelve month Return on Assets (ROA) is -49.22% as of 2026-06-30.
What is ZNTL's ROIC (return on invested capital)?
Zentalis Pharmaceuticals, Inc. (ZNTL)'s trailing twelve month Return on Invested Capital (ROIC) is -87.38% as of 2026-06-30.
What is ZNTL's EV/EBITDA?
Zentalis Pharmaceuticals, Inc. (ZNTL)'s trailing twelve month EV/EBITDA is -2.09x as of 2026-06-30.